Zanubrutinib MoA

Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). Watch the mode of action (MoA) video to learn more.

nF$:cU:Tm$mc n;8;7MGGG9 Ju i Epcss _-0L#~0LU [}vYY9 WjxmomrSHGHjh (??d)d?~(vsd 4So4p4S]J /C ,5ZbS{=z*L}J|/ oCwITTqJ L+T8=n zO^LL. _t CY F7AAHJtuf gcN?c 3W%uC%?3Y `7 f ;_YQx 4Jy!R,yJD! R&5Z5RQ& 03:],/ *0z^0w5 gzc]azzoG \8 ^ ?Jf9+f&j@ W/Y/tX[c2SV Lu# Kk MeqU_C+T_eC /~P5 qH)P_ P[,S+BH,` -n z,oQz QX6Jn`s )-s,qq lKB{+XKX${5d. 9b7hy_hIZ7Zy +p 1PP:pF#r #*0 G7; ?E{s?({Q? wf p5r\5 1pnW(hn7 Kmel XbrFqgU`Tö7’U KWEP#`L#GgLvX^KvW \X-l #c! M`3n u/8/fZ/G tU 3aj4X @YV UNy4N NSExpvS 1G gIE m,Z @D$[:7^DLp bO)Tbc)Sb }} ,U+uo_+C ?@Q?{w|s?\ W0b 1`Z,)IH,,wu)v`Z%-:&.

Please login or register for full access

Register

Already registered?  Login